vs
Side-by-side financial comparison of ECARX Holdings Inc. (ECX) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
ECARX Holdings Inc. is the larger business by last-quarter revenue ($323.3M vs $168.4M, roughly 1.9× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 6.5%).
ECARX Holdings Inc. is a global mobility technology provider specializing in integrated smart vehicle solutions, including in-vehicle infotainment systems, advanced driver assistance technologies, and connected car cloud services. It primarily partners with automotive manufacturers across the world, with a strong operational presence in the Chinese and European markets.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
ECX vs ESPR — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $323.3M | $168.4M |
| Net Profit | $-69.1M | — |
| Gross Margin | 15.5% | — |
| Operating Margin | -20.2% | 50.6% |
| Net Margin | -21.4% | — |
| Revenue YoY | 6.5% | 143.7% |
| Net Profit YoY | 12.8% | — |
| EPS (diluted) | $-0.20 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $168.4M | ||
| Q3 25 | — | $87.3M | ||
| Q2 25 | $323.3M | $82.4M | ||
| Q1 25 | — | $65.0M | ||
| Q4 24 | — | $69.1M | ||
| Q3 24 | — | $51.6M | ||
| Q2 24 | $303.5M | $73.8M | ||
| Q1 24 | — | $137.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-31.3M | ||
| Q2 25 | $-69.1M | $-12.7M | ||
| Q1 25 | — | $-40.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-29.5M | ||
| Q2 24 | $-79.2M | $-61.9M | ||
| Q1 24 | — | $61.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 15.5% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 22.6% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 50.6% | ||
| Q3 25 | — | -11.4% | ||
| Q2 25 | -20.2% | 8.6% | ||
| Q1 25 | — | -34.0% | ||
| Q4 24 | — | -6.4% | ||
| Q3 24 | — | -31.0% | ||
| Q2 24 | -22.2% | 3.5% | ||
| Q1 24 | — | 52.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | -35.9% | ||
| Q2 25 | -21.4% | -15.4% | ||
| Q1 25 | — | -62.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -57.2% | ||
| Q2 24 | -26.1% | -83.9% | ||
| Q1 24 | — | 44.3% |
| Q4 25 | — | $0.32 | ||
| Q3 25 | — | $-0.16 | ||
| Q2 25 | $-0.20 | $-0.06 | ||
| Q1 25 | — | $-0.21 | ||
| Q4 24 | — | $-0.14 | ||
| Q3 24 | — | $-0.15 | ||
| Q2 24 | $-0.23 | $-0.33 | ||
| Q1 24 | — | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.2M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-293.7M | $-302.0M |
| Total Assets | $494.9M | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $167.9M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | $86.2M | $86.1M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | — | $144.8M | ||
| Q3 24 | — | $144.7M | ||
| Q2 24 | $108.4M | $189.3M | ||
| Q1 24 | — | $226.6M |
| Q4 25 | — | $-302.0M | ||
| Q3 25 | — | $-451.4M | ||
| Q2 25 | $-293.7M | $-433.5M | ||
| Q1 25 | — | $-426.2M | ||
| Q4 24 | — | $-388.7M | ||
| Q3 24 | — | $-370.2M | ||
| Q2 24 | $-198.5M | $-344.2M | ||
| Q1 24 | — | $-294.3M |
| Q4 25 | — | $465.9M | ||
| Q3 25 | — | $364.0M | ||
| Q2 25 | $494.9M | $347.1M | ||
| Q1 25 | — | $324.0M | ||
| Q4 24 | — | $343.8M | ||
| Q3 24 | — | $314.1M | ||
| Q2 24 | $555.0M | $352.3M | ||
| Q1 24 | — | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.0M | $45.2M |
| Free Cash FlowOCF − Capex | $-86.5M | — |
| FCF MarginFCF / Revenue | -26.7% | — |
| Capex IntensityCapex / Revenue | 1.4% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $45.2M | ||
| Q3 25 | — | $-4.3M | ||
| Q2 25 | $-82.0M | $-31.4M | ||
| Q1 25 | — | $-22.6M | ||
| Q4 24 | — | $-35.0M | ||
| Q3 24 | — | $-35.3M | ||
| Q2 24 | $-57.1M | $-7.2M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-86.5M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | $-64.9M | $-7.3M | ||
| Q1 24 | — | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -26.7% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | -21.4% | -9.9% | ||
| Q1 24 | — | 39.0% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | 1.4% | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | 2.6% | 0.1% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ECX
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
